Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01198184
First received: September 8, 2010
Last updated: May 29, 2014
Last verified: October 2013

September 8, 2010
May 29, 2014
August 2010
July 2013   (final data collection date for primary outcome measure)
  • Recommended phase II dose defined as the dose level at which less than or equal to 1 of 6 patients experienced DLT assessed using NCI CTCAE version 4.0 [ Time Frame: 21 days ] [ Designated as safety issue: Yes ]
  • Safety profile assessed using NCI CTCAE version 4.0 [ Time Frame: Up to 4 weeks post-treatment ] [ Designated as safety issue: Yes ]
    Frequency and severity of adverse events will be tabulated using counts and proportions detailing frequently occurring, serious and severe events of interest. Attempts to model associations between pharmacokinetic data with toxicity profiles will be performed primarily using descriptive statistics, however, logistic regression may be used if warranted.
  • Recommended phase II dose of temsirolimus in combination with gamma-secretase inhibitor RO4929097 [ Designated as safety issue: Yes ]
  • Safety profile [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT01198184 on ClinicalTrials.gov Archive Site
  • Objective response to treatment assessed using the RECIST criteria 1.1 [ Time Frame: Up to 4 weeks post-treatment ] [ Designated as safety issue: No ]
    All analyses will be considered exploratory and inference will be performed with appropriate caution. For all statistical tests, two-sided tests will be performed and no p-value adjustment performed due to the exploratory nature of these tests. A p-value of 0.05 or less will be considered statistically significant.
  • Pharmacokinetic profiles [ Time Frame: Pre-dose, 0.5, 1, 2, 4, 6 and 24 hours ] [ Designated as safety issue: No ]
    All analyses will be considered exploratory and inference will be performed with appropriate caution. For all statistical tests, two-sided tests will be performed and no p-value adjustment performed due to the exploratory nature of these tests. A p-value of 0.05 or less will be considered statistically significant.
  • Pharmacodynamic effects [ Time Frame: Up to 4 weeks post-treatment ] [ Designated as safety issue: No ]
    All analyses will be considered exploratory and inference will be performed with appropriate caution. For all statistical tests, two-sided tests will be performed and no p-value adjustment performed due to the exploratory nature of these tests. A p-value of 0.05 or less will be considered statistically significant.
  • Pharmacokinetic profiles [ Designated as safety issue: No ]
  • Pharmacodynamic effects [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors
Safety and Efficacy of RO4929097 in Combination With Temsirolimus: A Pharmacokinetic and Pharmacodynamic Phase I Study in Patients With Advanced Solid Tumours With an Expansion of Cohort With Patients With Recurrent/Metastatic Endometrial and Renal Cell Cancers

This phase I trial is studying the side effects and best dose of giving gamma-secretase/Notch signalling pathway inhibitor RO4929097 and temsirolimus together in treating patients with advanced solid tumors. Gamma-secretase/Notch signalling pathway inhibitor RO4929097 and temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PRIMARY OBJECTIVES:

I. To determine the recommended phase II dose (RP2D) and safety profile of temsirolimus in combination with RO4929097 (gamma-secretase/Notch signalling pathway inhibitor RO4929097) in patients with advanced solid tumors.

SECONDARY OBJECTIVES:

I. To obtain pharmacokinetic (PK) profiles for both drugs when administered in combination in order to quantify the expected interactive effects in PK between these two agents.

II. To evaluate pharmacodynamic (PD) effects of both drugs when administered in combination, with the goal of identifying potential predictive and PD markers that need further exploration and validation in future trials.

OUTLINE: This is a multicenter, dose-escalation study.

Patients receive temsirolimus IV over 30 minutes on day -6 (course 1 only). Patients then receive temsirolimus IV or orally (PO) on days 1, 8, and 15 and gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Blood and tumor tissue samples may be collected periodically for pharmacokinetic and correlative analyses.

After completion of study treatment, patients are followed up for 4 weeks.

Interventional
Phase 1
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Endometrial Papillary Serous Carcinoma
  • Recurrent Endometrial Carcinoma
  • Recurrent Renal Cell Cancer
  • Stage III Endometrial Carcinoma
  • Stage III Renal Cell Cancer
  • Stage IV Endometrial Carcinoma
  • Stage IV Renal Cell Cancer
  • Unspecified Adult Solid Tumor, Protocol Specific
  • Drug: temsirolimus
    Given IV or PO
    Other Names:
    • CCI-779
    • cell cycle inhibitor 779
    • Torisel
  • Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
    Given PO
    Other Names:
    • R4733
    • RO4929097
  • Other: laboratory biomarker analysis
    Correlative studies
  • Other: pharmacological study
    Correlative studies
    Other Name: pharmacological studies
Experimental: Treatment (temsirolimus and RO4929097)
Patients receive temsirolimus IV over 30 minutes on day -6 (course 1 only). Patients then receive temsirolimus IV or PO on days 1, 8, and 15 and gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Interventions:
  • Drug: temsirolimus
  • Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
  • Other: laboratory biomarker analysis
  • Other: pharmacological study
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
18
October 2013
July 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Meets one of the following sets of criteria:

    • Dose-escalation group:

      • Histologically and/or cytologically confirmed solid malignancy
      • Metastatic or unresectable disease
      • Disease for which standard curative or palliative measures do not exist or are no longer effective
    • Expansion group:

      • Histologically and/or cytologically confirmed endometrial (endometrioid, uterine papillary serious carcinoma, or carcinosarcoma) or renal cell cancer
      • Metastatic or unresectable disease
      • Disease for which standard curative or palliative measures do not exist or are no longer effective
  • Measurable or non-measurable disease

    • Measurable disease is defined as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension (longest diameter to be recorded) as ≥ 20 mm with conventional techniques or as ≥ 10 mm with spiral CT scan
  • No known brain metastases
  • ECOG performance status (PS) 0-1 (Karnofsky PS 70-100%)
  • Life expectancy > 12 weeks
  • Leukocytes ≥ 3,000/mm^3
  • ANC ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Hemoglobin ≥ 90 g/L (or ≥ 9 g/dL)
  • Total bilirubin normal
  • AST/ALT ≤ 2.5 times upper limit of normal
  • Serum creatinine normal OR creatine clearance ≥ 60 mL/min
  • Fasting cholesterol ≤ 350 mg/dL (9.0 mmol/L)
  • Fasting triglycerides ≤ 400 mg/dL (4.56 mmol/L)
  • No uncontrolled hypocalcemia, hypomagnesemia, hyponatremia, hypophosphatemia or hypokalemia defined as less than the lower limit of normal for the institution, despite adequate electrolyte supplementation

    • Note: it is acceptable to use corrected calcium when interpreting calcium levels
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use two effective forms of contraception (i.e., barrier contraception and one other method of contraception) for ≥ 4 weeks before, during, and for ≥ 12 months after completion of study therapy
  • Able to swallow medication
  • No malabsorption syndrome or other condition that would interfere with intestinal absorption
  • No diarrhea ≥ grade 2 that is not under control with standard anti-diarrhea medications
  • No uncontrolled concurrent illness including, but not limited to, any of the following:

    • Ongoing or active infection
    • Symptomatic congestive heart failure
    • Unstable anginal pectoris
    • Cardiac arrhythmia other than chronic, stable atrial fibrillation
    • Psychiatric illness or social situations that would limit compliance with study medications
  • QTc ≤ 450 msec in males and a QTc ≤ 470 msec in females, as measured by ECG using Bazett formula
  • No history of risk factors for QT interval prolongation including, but not limited to, a family or personal history of any of the following:

    • Long QT syndrome
    • Torsades de pointes
    • Recurrent syncope without known etiology
    • Sudden unexpected death
  • No pre-existing significant pulmonary infiltrates of unknown origin
  • No serologic positivity for hepatitis A, B, or C or history of liver disease or other forms of hepatitis or cirrhosis
  • No HIV-positive patients on combination antiretroviral therapy
  • No history of allergic reactions attributed to compounds of similar chemical or biologic composition to gamma-secretase inhibitor RO4929097 or temsirolimus
  • Female patients may not donate ova during or after study treatment
  • Male patients may not donate sperm during and for ≥ 12 months after completion of study treatment
  • Patients may not donate blood during and for ≥ 12 months after completion of study treatment
  • Any number of prior therapies allowed
  • Recovered from side effects of previous systemic anticancer therapy to < CTCAE grade 2 toxicity (except alopecia)
  • Concurrent leuteinizing hormone-releasing hormone agonist allowed in patients with castration-resistant prostate cancer
  • No prior gamma-secretase inhibitor or any inhibitor of the PI3K/Akt/mTOR pathway
  • At least 4 weeks since prior radiotherapy or systemic therapy (6 weeks for carmustine, nitrosoureas, or mitomycin C)

    • Exceptions may be made for low-dose, non-myelosuppressive radiotherapy for symptomatic palliation
  • No other concurrent investigational agents
  • No concurrent medications with narrow therapeutic indices that are metabolized by cytochrome P450 (CYP450), including warfarin sodium (Coumadin®)
  • No concurrent medications that are strong inducers, inhibitors, or substrates of CYP3A4
  • No antiarrhythmics or other concurrent medications with known potential to prolong QT interval
  • No concurrent food that may interfere with the metabolism of gamma-secretase inhibitor RO4929097, including grapefruit or grapefruit juice
  • No other concurrent anticancer agents or therapies
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT01198184
NCI-2011-02529, NCI-2011-02529, 8500, CDR0000684714, PJC-005, 8500, U01CA132123
Not Provided
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Not Provided
Principal Investigator: Amit Oza University Health Network-Princess Margaret Hospital
National Cancer Institute (NCI)
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP